16 May DRC Director's Report - May 2022 May 16, 2022 By The Fraternal Order of Eagles Diabetes Research Center DRC, Diabetes, Diabetes Research Center, Iowa, Charity Foundation 0 Obesity causes a buildup of fat metabolites, including a toxic lipid molecule ceramide. Buildup of ceramide worsens health because it contributes to the development of diabetes and other diseases. Previous work has shown that targeting ceramide is an effective strategy to treat obesity, diabetes and associated cardiovascular disease. This can be achieved using a molecule called myriocin which is a very potent inhibitor of ceramide generation. Myriocin-mediated reduction of ceramide levels was found to be an effective way to treat obesity and associated diseases in rodents. Myriocin, which is not approved for use in humans, is abundant in a number of fungal species including the one called Cordyceps which is routinely consumed as part of traditional Chinese medicine used for the treatment of numerous diseases including diabetes. In a recently published study, FOEDRC member, Dr. Chaurasia, and his team screened extracts of Cordyceps currently being consumed by humans to identify those containing myriocin and tested their efficacy in improving body weight and glucose in obese animals. Interestingly, they identified several commercially available Cordyceps that contain myriocin. When they treated obese mice with a human equivalent dose of Cordyceps extract containing myriocin they found it was effective in reducing ceramide accumulation. This treatment was also successful in preventing obesity and improving blood glucose and liver disease. This study provides proof-of-principle that inhibiting the buildup of ceramide using myriocin containing Cordyceps extract improves not only obesity, but also diabetes and liver disease. Collectively, this work identifies commercially available Cordyceps as a readily available supplement to treat obesity and associated diseases. Related Articles DRC Director's Report - July 2022 Recently, the University of Iowa Fraternal Order of Eagles Diabetes Research Center (FOEDRC) held our annual Diabetes Research Day in collaboration with the University of Minnesota Institute for Diabetes, Obesity and Metabolism. This year, Diabetes Research Day was a hybrid event comprised of speakers from both institutions and split into two different events. Our first keynote speaker was Bryan Bergman, PhD. Professor in the Division of Endocrinology, Metabolism and Diabetes at the University of Colorado Anschutz Medical Campus who gave a talk entitled Intermuscular Adipose Tissue: A Novel Adipose Depot Impacting Muscle Strength, Size, and Insulin Sensitivity in Humans. DRC Director's Report - September 2022 Over the past decade, evidence has emerged indicating that high blood sugars in type 1 diabetes cause adverse brain changes in children. The adverse changes include abnormal brain structural alterations and reduced functioning on some cognitive tests. Over the past few years, hybrid closed-loop insulin pumps have become commercially available. These devices combine a continuous glucose monitor (CGM) with an insulin pump that is controlled by an algorithm that uses the CGM data to inform insulin delivery. DRC Director's Report - June 2022 On May 24, 2022, Fraternal Order of Eagles members joined the University of Iowa President, College of Medicine Executive Dean, faculty, staff and students for an investiture ceremony honoring three Carver of College of Medicine faculty. DRC Director's Report - August 2022 This June, the American Diabetes Association (ADA) hosted its 82nd Scientific Sessions in New Orleans, LA. Each year, thousands of attendees join together from across the world to hear the latest cutting-edge research. Sharing the latest scientific findings, the annual meeting is the largest and most important gathering focused on diabetes research. The ADA is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 82 years, the ADA has driven research to treat, manage and prevent diabetes while also working relentlessly for a cure. Diabetes is the most common underlying chronic condition in the United States. 133 million Americans currently live with diabetes or prediabetes and, in the last 20 years, the number of Americans with diagnosed diabetes has more than doubled. The ADA is focused on timely, critical advancements in diabetes research and care. DRC Director's Report - April 2022 A research team that includes several FOEDRC faculty recently published an article describing a new approach to help treat type 2 diabetes. The research team included FOEDRC faculty members Robert Kerns PhD, Andrew Norris MD PhD, Eric Taylor PhD, Yumi Imai MD, and Jessica Smith MD. Also recognized in the publication was Wojciech Grzesik, PhD, who is a research scientist in the FOEDRC metabolic phenotyping core. The work was published in the prestigious journal "Nature Communications" and can be found at this link : https://pubmed.ncbi.nlm.nih.gov/35145074/ DRC Director's Report - February 2022 On January 3rd, 2022, we celebrated the career of FOEDRC faculty member Dr. Eva Tsalikian on the occasion of her well-earned retirement. For over 4 decades, Dr. Tsalikian has been tireless in her pursuit of better treatments for children with diabetes. Her research work earned her the 2011 Mary Tyler Moore & S. Robert Levine Excellence in Clinical Diabetes Research award and she was the 2013 Honoree at the Eastern Iowa Juvenile Diabetes Research Foundation gala. Showing 0 Comment Comments are closed.